Death or cerebral palsy at 1 to 3 years · preterm infants at risk for bronchopulmonary dysplasia
Lower showed no clear difference in death or cerebral palsy at 1 to 3 years compared with higher cumulative dose dexamethasone regimen (low certainty).
1 finding from 1 review
Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether lower changes death or abnormal neurodevelopmental outcome (various definitions)… compared with higher cumulative dose dexamethasone regimen (very low certainty).
1 finding from 1 review
Intervention not reported
Total studies: 42 Total participants: 14,626 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
The intervention led to lower total studies: 42 Total participants: 14,626; GRADE not reported.
1 finding from 1 review
no estimate extracted
42 participants
GRADE not reported
Intervention not reported
Total studies: 50 Total participants: 14,926 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
50 participants
GRADE not reported
Intervention not reported
Duloxetine standard dose RCTs: 18 Participants: 4959 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
18 participants
Moderate
Intervention not reported
Milnacipran standard dose RCTs: 4 Participants: 1866 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
4 participants
Moderate
Intervention not reported
Duloxetine low dose RCTs: 6 Participants: 1104 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
6 participants
Moderate
Intervention not reported
Duloxetine standard dose RCTs: 16 Participants: 4490 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
1 finding from 1 review
no estimate extracted
16 participants
Moderate
Intervention not reported
Total studies: 93 Total participants: 22,558 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…
The intervention led to lower total studies: 93 Total participants: 22,558; GRADE not reported.
1 finding from 1 review
no estimate extracted
93 participants
GRADE not reported
Intervention not reported
Mirtazapine standard dose RCTs: 2 Participants: 457 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…
1 finding from 1 review
no estimate extracted
2 participants
Very low
Intervention not reported
Duloxetine standard dose RCTs: 20 Participants: 4998 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…
1 finding from 1 review
no estimate extracted
20 participants
Very low
Intervention not reported
Milnacipran standard dose RCTs: 8 Participants: 2491 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…
1 finding from 1 review
no estimate extracted
8 participants
Very low
Intervention not reported
Duloxetine low dose RCTs: 6 Participants: 1031 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…
1 finding from 1 review
no estimate extracted
6 participants
Very low
Intervention not reported
Amitriptyline standard dose RCTs: 10 Participants: 997 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…
1 finding from 1 review
no estimate extracted
10 participants
Very low
Intervention not reported
Esreboxetine standard dose RCTs: 1 Participants: 783 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…
1 finding from 1 review
no estimate extracted
1 participants
Very low
Intervention not reported
Esreboxetine standard dose RCTs: 1 Participants: 828 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
1 finding from 1 review
no estimate extracted
1 participants
Low
Intervention not reported
Milnacipran standard dose RCTs: 2 Participants: 1298 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
1 finding from 1 review
no estimate extracted
2 participants
Low
Intervention not reported
Mirtazapine standard dose RCTs: 1 Participants: 422 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
1 finding from 1 review
no estimate extracted
1 participants
Low
Intervention not reported
Duloxetine low dose RCTs: 6 Participants: 1116 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
1 finding from 1 review
no estimate extracted
6 participants
Moderate
Intervention not reported
All‐cause mortality at day 28 · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The intervention may leads to lower all‐cause mortality at day 28 (low certainty).
1 finding from 1 review